Cornea

According to the company, the study found a positive safety and tolerability profile for aCT1 for treatment of corneal injury.

The University of Oklahoma Health Sciences Center has received an unrestricted grant from Research to Prevent Blindness for $575,000 over 5 years to support eye research conducted by the Department of Ophthalmology.

Kala Pharmaceuticals Inc. announced that it has completed the sale of its commercial portfolio and related intellectual property assets to Alcon Inc., a transaction that was first announced in May.

According to William B. Trattler, MD, progression of the disease before cross-linking often can be identified over a period of months.

According to Mark Lobanoff, DO, earlier treatment also can mean the best possible results for patients.

Kiora Pharmaceuticals announced it has enrolled the first patient as a part of a Phase 2 study evaluating KIO-201 topical eye drops in patients with PCED, a rare ocular surface condition characterized by non-healing wounds on the eye surface.

RegeneRx Biopharmaceuticals Inc. said its U.S. joint venture partner and licensee, HLB Therapeutics, will expand its ophthalmic clinical development program with RGN-259 in two indications, neurotrophic keratopathy and dry eye disease.

A study by Orbis International found that children with myopia experienced significantly higher levels of depression and anxiety than their peers without vision impairment.

As dexamethasone adds indications, a study confirms efficacy of punctal occlusion for allergic conjunctivitis.

The treatments typically include application of heat, lid hygiene, and massage of eyelid.

According to researchers from the Doherty Institute, the cornea produces a delicate and limited immune response to fight infections without damaging a patient's vision.

The Phase 3 registrational study is examining AR-15512, a differentiated, novel product candidate for the treatment of the signs and symptoms of Dry Eye Disease

According to the companies, Kala will receive $60 million in upfront payment, and could be eligible to receive additional sales-based milestone payments.

The study evaluates three separate cases, each which experiences irreversible changes in their corneal structure caused by challenges in getting timely treatment due to various reasons, including insurance, lost to follow up, and the coronavirus pandemic.

At ARVO 2022 in Denver, Colorado, Timothy Blenkinsop, MD, presented “3D Eye Organoids with Distinct Cornea.” His presentation outlined how these organoids have developed sophisticated cornea structures.

The study's primary endpoints were to look at increasing Schirmer's scores, as well as eye discomfort score.

Takeaway: there doesn't seem to be a specific dry eye phenotype that does better or worse.

Patients are at risk for developing severe dry eye and ocular surface disease.

In a poster presented at the Association for Research in Vision and Ophthalmology’s 2022 annual meeting in Denver, Mamoru Ogawa, MD, noted that investigators have found that the choroidal and central corneal thicknesses increased over a very short period of time following intensive outdoor activity.

Philip Dockery, MD, MPH, discusses his paper "Corneal cross linking for progressive keratoconus, a retrospective analysis of 515 consecutive eyes," with Ophthalmology Times' David Hutton.

In an e-poster presented at the American Society of Cataract and Refractive Surgery’s 2022 annual meeting in Washington, D.C., Abdelrahman M. Elhusseiny, MD, MSc, noted a research team found that cenegermin was effective for improving the corneal healing in these pediatric patients.

Cynthia Matossian, MD, shares her thoughts on the premium patient "experience" or "journey," emphasizing the outcomes of patient experiences.

Assessing cornea status can aid early recognition of disease-related changes

Investigators theorize that the ophthalmic nerve may be affected by the COVID-19 virus, and therefore may affect the corneal esthesiometry values.

According to the company, VVN001 demonstrated clinical and statistical superiority over vehicle in reducing total and sub-regional corneal fluorescein staining scores.

"Tell Me Your Secrets" is the theme of the virtual April 2 event, which is expected to build on the foundation established during the first program held last fall.

Short-term steroid use can alleviate patient discomfort.

While investigators have found a link between dry eye and depression, the exact reasons behind the link are not immediately known.

The company’s iLink therapy for the treatment of keratoconus consists of novel single-use drug formulations that are bio-activated by proprietary systems through the delivery of ultraviolet light to the cornea to induce corneal cross-linking designed to strengthen, stabilize and reshape the cornea.

Lisa M. Nijm, MD, JD, previews the program for this April 2 virtual event designed to help young ophthalmologists learn everything they need to know when starting practice.